- $504.78m
- -$62.82m
- $262.60m
Brief: Arvinas Inc - 8-K SEC Filing
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
Arvinas Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Arvinas Q3 Basic EPS USD -0.68 Vs. IBES Estimate USD -0.96
Brief: Arvinas Inc Says On August 15 Unit Co Entered Into A Lease Termination Agreement With 101 College Street
Brief: Arvinas Q2 Basic EPS USD -0.49 Vs. IBES Estimate USD -0.86
Brief: Hookipa Pharma Announces Leadership Changes To Intensify Focus On HB-200
Brief: Arvinas Inc Says Unit Entered Into An Amended And Restated License Agreement With Yale University
Brief: Arvinas- Due To Hart-Scott-Rodino Termination & Satisfaction Of Closing Conditions Of License Agreement, Asset Agreement, Novartis Pharma AG To Pay Co $150.0 Million
Arvinas climbs on positive data from breast cancer treatment trial
Brief: Arvinas, Pfizer Announce Updated Clinical Data From Phase 1B Trial Of Vepdegestrant In Combination With Palbociclib
U.S. RESEARCH ROUNDUP- Adtran Holdings, McKesson, Waters Corp
Arvinas Inc reports results for the quarter ended in March - Earnings Summary
Brief: Arvinas Q1 Basic EPS USD -0.97 Vs. IBES Estimate USD -1.41
Arvinas Inc expected to post a loss of $1.41 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
U.S. STOCKS ON THE MOVE-DoorDash, Devon Energy, Arvinas
Novartis licenses Arvinas' cancer drug for up to $1 billion (updated)